These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 35948211)
1. Tamoxifen Retinopathy and Macular Telangiectasia Type 2: Similarities and Differences on Multimodal Retinal Imaging. Hess K; Park YJ; Kim HA; Holz FG; Charbel Issa P; Yoon YH; Tzaridis S Ophthalmol Retina; 2023 Feb; 7(2):101-110. PubMed ID: 35948211 [TBL] [Abstract][Full Text] [Related]
2. Epiretinal Neovascularization: A Novel OCT Angiography Finding in Macular Telangiectasia Type 2. Ayachit AG; Reddy LU; Joshi S; Ayachit GS Ophthalmol Retina; 2019 Jun; 3(6):516-522. PubMed ID: 31174674 [TBL] [Abstract][Full Text] [Related]
3. OCT Angiography Findings of Tamoxifen Retinopathy: Similarity with Macular Telangiectasia Type 2. Lee S; Kim HA; Yoon YH Ophthalmol Retina; 2019 Aug; 3(8):681-689. PubMed ID: 31068263 [TBL] [Abstract][Full Text] [Related]
4. Progression of vascular changes in macular telangiectasia type 2: comparison between SD-OCT and OCT angiography. Pauleikhoff D; Gunnemann F; Book M; Rothaus K Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1381-1392. PubMed ID: 31093765 [TBL] [Abstract][Full Text] [Related]
5. Multimodal Imaging of Macular Telangiectasia Type 2: Focus on Vascular Changes Using Optical Coherence Tomography Angiography. Toto L; Di Antonio L; Mastropasqua R; Mattei PA; Carpineto P; Borrelli E; Rispoli M; Lumbroso B; Mastropasqua L Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT268-76. PubMed ID: 27409482 [TBL] [Abstract][Full Text] [Related]
6. Potential Effects of Hormone Therapy in Type 2 Idiopathic Macular Telangiectasia. Wolf-Schnurrbusch UEK; Leung I; Sallo FB; Clemons TE; Chew EY; Bird AC; Peto T; Ophthalmic Res; 2018; 60(1):38-42. PubMed ID: 28903123 [TBL] [Abstract][Full Text] [Related]
7. Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the MacTel Area: MacTel Project Report Number 8. Heeren TFC; Chew EY; Clemons T; Fruttiger M; Balaskas K; Schwartz R; Egan CA; Charbel Issa P; Ophthalmology; 2020 Nov; 127(11):1539-1548. PubMed ID: 32586743 [TBL] [Abstract][Full Text] [Related]
8. Staging of macular telangiectasia: power-Doppler optical coherence tomography and macular pigment optical density. Chin EK; Kim DY; Hunter AA; Pilli S; Wilson M; Zawadzki RJ; Werner JS; Park SS Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4459-70. PubMed ID: 23716628 [TBL] [Abstract][Full Text] [Related]
9. EARLY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS TO CONFIRM FELLOW EYE CHANGES IN ASYMMETRIC TYPE-2 MACULAR TELANGIECTASIA: A Case-Control Study (India Macular Telangiectasia Report 1). Alex D; Giridhar A; Gopalakrishnan M; Manayath G; Amar S; Raman R; Sreenivasan R; Ayachit A; Sivaprasad S Retina; 2021 Mar; 41(3):471-479. PubMed ID: 32804830 [TBL] [Abstract][Full Text] [Related]
10. OUTER FOVEAL DEFECTS IN TYPE-2 MACULAR TELANGIECTASIA. Chandran K; Giridhar A; Gayathri MS; Antison M; Gopalakrishnan M; Sivaprasad S Retina; 2023 Jan; 43(1):111-119. PubMed ID: 36542082 [TBL] [Abstract][Full Text] [Related]
11. Fundus Autofluorescence Imaging in Macular Telangiectasia Type 2: MacTel Study Report Number 9. Pauleikhoff L; Heeren TFC; Gliem M; Lim E; Pauleikhoff D; Holz FG; Clemons T; Balaskas K; ; Egan CA; Charbel Issa P Am J Ophthalmol; 2021 Aug; 228():27-34. PubMed ID: 33775659 [TBL] [Abstract][Full Text] [Related]